Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan
Background: Injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) are proven to be well tolerated and efficacious in people with type 2 diabetes mellitus (T2DM) fasting during Ramadan. The first oral GLP-1RA semaglutide, also indicated for the treatment of T2DM, has specific dosing instruc...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2022-12-01
|
| Series: | Dubai Diabetes and Endocrinology Journal |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/527475 |
| _version_ | 1797948022711123968 |
|---|---|
| author | Mohamed Hassanein Abdulqawi Almansari Ebtesam Ba-Essa Fatheya F. Alawadi Hussein ElBadawi Rakesh Kumar Sahay Rayaz Malik Rohana Abdul Ghani Salah Abusnana Shehla Shaikh Sueziani Binte Zainudin Tarik Elhadd Yousef AL Saleh |
| author_facet | Mohamed Hassanein Abdulqawi Almansari Ebtesam Ba-Essa Fatheya F. Alawadi Hussein ElBadawi Rakesh Kumar Sahay Rayaz Malik Rohana Abdul Ghani Salah Abusnana Shehla Shaikh Sueziani Binte Zainudin Tarik Elhadd Yousef AL Saleh |
| author_sort | Mohamed Hassanein |
| collection | DOAJ |
| description | Background: Injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) are proven to be well tolerated and efficacious in people with type 2 diabetes mellitus (T2DM) fasting during Ramadan. The first oral GLP-1RA semaglutide, also indicated for the treatment of T2DM, has specific dosing instructions to optimize treatment exposure, which may need to be altered during Ramadan fasting to ensure optimal efficacy. Summary: Given the lack of current published evidence for the effect of oral semaglutide during Ramadan, a panel of experts formulated recommendations for the administration of oral semaglutide during Ramadan. Key Messages: This statement reports recommendations for oral semaglutide administration during Ramadan. |
| first_indexed | 2024-04-10T21:36:57Z |
| format | Article |
| id | doaj.art-51a30c787ce4441fbce478e0b677f358 |
| institution | Directory Open Access Journal |
| issn | 2673-1797 2673-1738 |
| language | English |
| last_indexed | 2024-04-10T21:36:57Z |
| publishDate | 2022-12-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Dubai Diabetes and Endocrinology Journal |
| spelling | doaj.art-51a30c787ce4441fbce478e0b677f3582023-01-19T10:35:14ZengKarger PublishersDubai Diabetes and Endocrinology Journal2673-17972673-17382022-12-0128413113510.1159/000527475527475Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during RamadanMohamed Hassanein0Abdulqawi Almansari1Ebtesam Ba-Essa2Fatheya F. Alawadi3https://orcid.org/0000-0001-8911-866XHussein ElBadawi4Rakesh Kumar Sahay5https://orcid.org/0000-0002-5471-0695Rayaz Malik6https://orcid.org/0000-0002-7188-8903Rohana Abdul Ghani7https://orcid.org/0000-0002-3520-8472Salah Abusnana8Shehla Shaikh9Sueziani Binte Zainudin10Tarik Elhadd11Yousef AL Saleh12Dubai Hospital, Mohamed Bin Rashid University, Dubai, United Arab EmiratesMy Clinic International Center, Endocrinology and Diabetes, Jeddah, Saudi ArabiaDepartment of Endocrinology, Sumuo Medical Center, Alkhobar, Saudi ArabiaDubai Hospital, Endocrine Department, Dubai Health Authority, Dubai, United Arab EmiratesMy Clinic International, Endocrinology, Jeddah, Saudi ArabiaDepartment of Endocrinology, Osmania Medical College, Hyderabad, IndiaWeill Cornell Medicine, Doha, QatarDepartment of Internal Medicine, Universiti Teknologi MARA (UiTM), Shah Alam, MalaysiaUniversity Hospital Sharjah, University of Sharjah, Sharjah, United Arab EmiratesSaifee Hospital, Endocrinology, Mumbai, IndiaSengkang General Hospital, Endocrinology, General Medicine, Sengkang, Singapore, SingaporeHamad Medicinal Corporation, Medicine, Doha, QatarDepartment of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, King Abdulaziz Medical City, Riyadh, Saudi ArabiaBackground: Injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) are proven to be well tolerated and efficacious in people with type 2 diabetes mellitus (T2DM) fasting during Ramadan. The first oral GLP-1RA semaglutide, also indicated for the treatment of T2DM, has specific dosing instructions to optimize treatment exposure, which may need to be altered during Ramadan fasting to ensure optimal efficacy. Summary: Given the lack of current published evidence for the effect of oral semaglutide during Ramadan, a panel of experts formulated recommendations for the administration of oral semaglutide during Ramadan. Key Messages: This statement reports recommendations for oral semaglutide administration during Ramadan.https://www.karger.com/Article/FullText/527475fastingoral semaglutideramadanrecommendationstype 2 diabetes |
| spellingShingle | Mohamed Hassanein Abdulqawi Almansari Ebtesam Ba-Essa Fatheya F. Alawadi Hussein ElBadawi Rakesh Kumar Sahay Rayaz Malik Rohana Abdul Ghani Salah Abusnana Shehla Shaikh Sueziani Binte Zainudin Tarik Elhadd Yousef AL Saleh Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan Dubai Diabetes and Endocrinology Journal fasting oral semaglutide ramadan recommendations type 2 diabetes |
| title | Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan |
| title_full | Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan |
| title_fullStr | Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan |
| title_full_unstemmed | Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan |
| title_short | Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan |
| title_sort | recommendations for titration and administration of oral semaglutide for the treatment of type 2 diabetes during ramadan |
| topic | fasting oral semaglutide ramadan recommendations type 2 diabetes |
| url | https://www.karger.com/Article/FullText/527475 |
| work_keys_str_mv | AT mohamedhassanein recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT abdulqawialmansari recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT ebtesambaessa recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT fatheyafalawadi recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT husseinelbadawi recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT rakeshkumarsahay recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT rayazmalik recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT rohanaabdulghani recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT salahabusnana recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT shehlashaikh recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT suezianibintezainudin recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT tarikelhadd recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan AT yousefalsaleh recommendationsfortitrationandadministrationoforalsemaglutideforthetreatmentoftype2diabetesduringramadan |